Shared Control: Novel Trial Design Works In COVID, But Will Sponsors Buy In?
Executive Summary
COVID-19 has helped demonstrate the viability of platform trials with a shared control arm. That model is easier to extol than it is for sponsors to embrace, especially outside of crisis mode.
You may also be interested in...
EMA Consults On Need For New Guide To Enable Confirmatory Platform Trials
The European Medicines Agency believes that a scientific guideline on clinical trials incorporating a platform design is needed because such studies are expected to play an increasingly important role in future marketing authorization applications.
EU Offers Advice On Running Complex Clinical Trials Under CTR
New EU-wide guidance describes the factors that sponsors should consider when designing and conducting trials with complex innovative designs.
How The EU Is Keeping Up With Innovation In Clinical Trials
A senior EMA official says Europe has set the ball rolling on presenting a unified approach on clinical trial processes and strategic matters, and is taking steps to ensure there are no roadblocks.